SURAKSHA
Suraksha Diagnostic Limited operates a chain of diagnostic centers in India. It offers pathology testing services, such as microbiology, serology, molecular biology, histopathology, cytopathology, clinical pathology, and haematology; genomics testing, including microarray, noninvasive prenatal, quantitative fluorescent polymerase chain reaction, fluorescence in situ hybridization, and karyotyping… Read more
SURAKSHA (SURAKSHA) - Net Assets
Latest net assets as of September 2025: ₹2.29 Billion INR
Based on the latest financial reports, SURAKSHA (SURAKSHA) has net assets worth ₹2.29 Billion INR as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₹3.80 Billion) and total liabilities (₹1.51 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₹2.29 Billion |
| % of Total Assets | 60.33% |
| Annual Growth Rate | 13.6% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 4.16 |
SURAKSHA - Net Assets Trend (2021–2025)
This chart illustrates how SURAKSHA's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for SURAKSHA (2021–2025)
The table below shows the annual net assets of SURAKSHA from 2021 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-03-31 | ₹2.10 Billion | +17.35% |
| 2024-03-31 | ₹1.79 Billion | +15.24% |
| 2023-03-31 | ₹1.55 Billion | +6.61% |
| 2022-03-31 | ₹1.46 Billion | +15.53% |
| 2021-03-31 | ₹1.26 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to SURAKSHA's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 122.3% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (March 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | ₹1.54 Billion | 72.96% |
| Common Stock | ₹104.16 Million | 4.93% |
| Other Comprehensive Income | ₹2.11 Million | 0.10% |
| Other Components | ₹464.83 Million | 22.01% |
| Total Equity | ₹2.11 Billion | 100.00% |
SURAKSHA Competitors by Market Cap
The table below lists competitors of SURAKSHA ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
ALBIS LEASING AG - Dusseldorf Stock Exchang
DU:ALG
|
$27.40K |
|
NQ Minerals Plc
OTCQB:NQMLF
|
$27.48K |
|
GRUPO BIMBO-A (4GM.SG)
STU:4GM
|
$27.48K |
|
DOUJA PROM ADDOHA
BC:DOUJA-PROM-ADDOHA
|
$27.49K |
|
ADVANCED EMISSIONS
BE:OXQ1
|
$27.39K |
|
AD PEPPER MEDIA - Dusseldorf Stock Exchang
DU:APM
|
$27.36K |
|
Clarocity Corp
PINK:CLRYF
|
$27.36K |
|
Igis Value Plus Reit Co Ltd
KO:334890
|
$27.34K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in SURAKSHA's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 1,794,080,000 to 2,112,397,000, a change of 318,317,000 (17.7%).
- Net income of 318,241,000 contributed positively to equity growth.
- Other comprehensive income increased equity by 2,111,999.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₹318.24 Million | +15.07% |
| Other Comprehensive Income | ₹2.11 Million | +0.1% |
| Other Changes | ₹-2.04 Million | -0.1% |
| Total Change | ₹- | 17.74% |
Book Value vs Market Value Analysis
This analysis compares SURAKSHA's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 6.47x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 10.83x to 6.47x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-03-31 | ₹23.68 | ₹256.30 | x |
| 2022-03-31 | ₹28.00 | ₹256.30 | x |
| 2023-03-31 | ₹29.94 | ₹256.30 | x |
| 2024-03-31 | ₹34.45 | ₹256.30 | x |
| 2025-03-31 | ₹39.63 | ₹256.30 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently SURAKSHA utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 15.07%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 12.62%
- • Asset Turnover: 0.76x
- • Equity Multiplier: 1.58x
- Recent ROE (15.07%) is above the historical average (10.36%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | 5.10% | 4.60% | 0.82x | 1.36x | ₹-61.87 Million |
| 2022 | 14.28% | 9.33% | 0.81x | 1.89x | ₹62.40 Million |
| 2023 | 4.18% | 3.43% | 0.68x | 1.80x | ₹-90.77 Million |
| 2024 | 13.17% | 10.80% | 0.73x | 1.67x | ₹56.85 Million |
| 2025 | 15.07% | 12.62% | 0.76x | 1.58x | ₹107.00 Million |
Industry Comparison
This section compares SURAKSHA's net assets metrics with peer companies in the Diagnostics & Research industry.
Industry Context
- Industry: Diagnostics & Research
- Average net assets among peers: $8,570,771,433
- Average return on equity (ROE) among peers: 17.27%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| SURAKSHA (SURAKSHA) | ₹2.29 Billion | 5.10% | 0.66x | $27.40K |
| Krsnaa Diagnostics Limited (KRSNAA) | $6.69 Billion | 10.23% | 0.31x | $119.95 Million |
| Dr. Lal Path Labs Ltd. (LALPATHLAB) | $1.17 Billion | 38.19% | 0.51x | $1.16 Billion |
| Metropolis Healthcare Limited (METROPOLIS) | $9.91 Billion | 14.42% | 0.52x | $557.10 Million |
| SAI LIFE SCIENCES LTD (SAILIFE) | $8.88 Billion | 1.12% | 1.46x | $1.01 Billion |
| Syngene International Limited (SYNGENE) | $36.18 Billion | 12.84% | 0.61x | $834.43 Million |
| Thyrocare Technologies Limited (THYROCARE) | $1.02 Billion | 34.10% | 0.34x | $258.97 Million |
| Vijaya Diagnostic Centre Limited (VIJAYA) | $3.59 Billion | 23.52% | 0.51x | $530.99 Million |
| Vimta Labs Limited (VIMTALABS) | $1.12 Billion | 3.75% | 0.29x | $72.56 Million |